Sign in

    Lander Egaña-Gorroño • H.C. Wainwright & Co., LLC

    Lander Egaña-Gorroño is an Equity Research Analyst at H.C. Wainwright & Co., LLC, specializing in life sciences and biotechnology sector research. He provides coverage for companies in the biotech space, delivering investment analysis and recommendations that contribute to institutional decision-making, though detailed metrics on his performance, such as TipRanks rankings or success rates, are not publicly disclosed. Egaña-Gorroño joined H.C. Wainwright after earning advanced qualifications in the biomedical field and holds industry-standard FINRA securities licenses, leveraging his scientific background to inform in-depth company evaluations. His career is distinguished by a commitment to scientific rigor and financial analysis, supporting investor strategies in rapidly developing healthcare markets.

    Lander Egaña-Gorroño's questions to BioCardia Inc (BCDA) leadership

    Lander Egaña-Gorroño's questions to BioCardia Inc (BCDA) leadership • Q2 2025

    Question

    Lander Egaña-Gorroño of H.C. Wainwright & Co., LLC inquired about the regulatory expectations for CardiAmp in Japan, specifically the differences in review processes for a point-of-care medical device versus a lab-manufactured therapy, and asked for confirmation on the upcoming Q4 data release for the CardiAmp CMI program.

    Answer

    CEO Peter Altman explained that the PMDA approval process for a medical device is seen as a lower hurdle, especially since nothing is left behind in the patient. He highlighted Japan's cultural preference for autologous therapies due to low organ transplant rates, positioning CardiAmp favorably. He noted that Japan's PMDA can grant conditional approvals with post-marketing studies. Dr. Altman also confirmed the upcoming Q4 data for the CardiAmp CMI program relates to the six-month primary endpoint results for the rolling cohort.

    Ask Fintool Equity Research AI